Beetham Thomas W.
SEC CIK 1741382 · EDGAR
BoughtSold
Most active insiders at VRDN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir, 10% | $20.00M | — |
| 2 | Fairmount Healthcare Fund II GP LLC | Dir, 10% | $10.00M | — |
| 3 | Tousignant Jennifer | CLO | — | $419.0K |
| 4 | Harmon Seth | CFO | — | — |
| 5 | Tripuraneni Radhika | Chief Medical Off | — | — |
| 6 | Mahoney Stephen F. | Pres, CEO, Dir | — | — |
| 7 | Beetham Thomas W. | COO | — | — |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2026-03-09 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Beetham Thomas W. | COO | F - Tax | $30.19 | -3,048 | 13.4K | -19% | -$92.0K |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Beetham Thomas W. | COO | M - OptEx | — | +9,409 | 16.4K | +134% | — |
| D | 2026-03-04 | 2026-03-03 | VRDN | Viridian Therapeutics, Inc.\DE | Beetham Thomas W. | COO | F - Tax | $29.32 | -3,138 | 13.3K | -19% | -$92.0K |
| 2024-09-30 | 2024-09-27 | VRDN | Viridian Therapeutics, Inc.\DE | Beetham Thomas W. | COO | P - Purchase | $23.41 | +5,000 | 6,000 | +500% | +$117.0K | |
| 2022-12-02 | 2022-11-30 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Beetham Thomas W. | See Remarks | A - Grant | $0.94 | +3,000 | 19.9K | +18% | +$2,820 | |
| 2022-06-06 | 2022-05-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Beetham Thomas W. | See Remarks | A - Grant | $0.99 | +3,000 | 16.9K | +22% | +$2,970 | |
| 2021-09-20 | 2021-09-16 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Beetham Thomas W. | See Remarks | S - Sale | $6.73 | -6,103 | 13.9K | -31% | -$41.1K | |
| 2021-09-16 | 2021-09-14 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Beetham Thomas W. | See Remarks | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations